Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Equity Premium Income ETF (JEPI) vs Moderna, Inc. (MRNA) Price & Performance

JPMorgan Equity Premium Income ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

JPMorgan Equity Premium Income ETF vs Moderna, Inc. — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.88, while Moderna, Inc. trades at $63.68 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

JEPIMRNA
Sector
Income / Options OverlayHealth
52-Week High
$59.88$81.80
52-Week Low
$55.29$22.36
Market Cap
$24.18B
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Equity Premium Income ETF

JEPI trades at $57.84, up 0.35% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent dividends of $0.39 and $0.37 highlight its income focus, while news coverage emphasizes its role in retirement portfolios amid competitive yield pressures from peers like SPYI and JEPQ.

The outlook is mixed: strong income appeal supports demand, but underperformance versus covered-call peers and tax inefficiencies risk long-term returns. Investors face trade-offs between monthly distributions and capital appreciation, with sentiment divided on whether JEPI's strategy justifies opportunity costs.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Equity Premium Income ETF

JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.

Read more on JEPI

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA